Product
ARGX-119
3 clinical trials
3 indications
Indication
Healthy Control ParticipantsIndication
Amyotrophic lateral sclerosisIndication
Congenital Myasthenic SyndromeClinical trial
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy ParticipantsStatus: Recruiting, Estimated PCD: 2024-08-02
Clinical trial
A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral SclerosisStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic SyndromesStatus: Not yet recruiting, Estimated PCD: 2025-10-01